Genzyme looks to integrate up and downstream for continuous biomanufacturing

By Dan Stanton contact

- Last updated on GMT

Sanofi's Genzyme files patent for upstream/downstream continuous manufacturing technology
Sanofi's Genzyme files patent for upstream/downstream continuous manufacturing technology

Related tags: Biotechnology, Chemical engineering

Genzyme has filed a patent application for a technology platform that will bridge the gap between upstream and downstream processing in continuous biomanufacturing. 

Entitled ‘Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances,’​ Genzyme claims the platform feeds a liquid culture medium containing the biologic manufactured through perfusion into a first multi-column chromatography system (MCCS1), capturing the therapeutic protein and then continuously fed into a second chromatography system where it is purified and polished.

While perfusion has brought continuous manufacturing to the upstream process, there are limited methods that utilise a fully continuous end-to-end process, according to Chris Hwang, Senior Director of Late Stage Process Development at Genzyme.

“Integration of upstream and downstream process in continuous biomanufacturing is the new kid on the block compare to traditional perfusion or batch/fed-batch upstream follow by batch downstream processes.”​ Hwang told Biopharma-Reporter.com, and "therefore comes with significant upward potential."

“It can be used to produce any biologics (stable or labile proteins) and provides many important strategic advantages,”​ he continued, including a smaller production foot print, lower OPEX/CAPEX, enhanced product quality, flexible capacity management, minimised tech transfer risks and facilitated manufacturing standardisation. "It is for these advantages that FDA [US Food and Drug Administration] has been encouraging the industry to consider the continuous manufacturing methodology," ​he added.

For this potential new offering “some of the enabling technologies are currently available on the market and any gaps in the technology have been developed internally,” ​Hwang told us.

According to the patent application, the technology was invented by four scientists all working for Genzyme – the biotech wing of French firm Sanofi.

Perfusion

Perfusion is a process where suspension cell culture is constantly supplied with fresh medium to the bioreactor while spent culture media is harvested without interruption for up to 90 days, and has already been adopted by a number of biomanufacturers including Janssen​ and SAFC​.

According to a paper published in BioProcessingjournal.com​, perfusion generally provides more product than fed-batch manufacture even when using smaller bioreactors and authors Eric Langer of BioPlan Associates and Ronald Radar from the Biotechnology Information Institute say this is driving industry’s adoption in continuous processes.

Furthermore, “as new downstream, continuous processing technologies start to become available, it will ultimately become feasible to perform full end-to-end bioprocessing, both up and downstream,”​ the paper said, further reducing costs of bioprocessing compared with batch manufacturing.

Limitations?

We asked Hwang whether there were limitations with implementing continuous biomanufacturing in the industry.

“In our experience, thus far there aren’t any technical challenges we can’t overcome. However given that it is fairly new, it needs sufficient at scale and manufacturing experience before it can transform into a mature production platform.”

However, he continued, the “deeply entrenched mental models associated with batch/fed-batch processes,” ​remain a challenge within the industry, but Genzyme was looking to overcome this by engaging end users and design with the end in mind, and forming strategic partnerships with vendors, along with producing “data, data, and data!”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars